BIO and California Associations Challenge GLOBE Drug Pricing Model
BIO and two California associations are challenging the GLOBE model in federal court, arguing that international drug pricing benchmarks could undermine investment in new therapies. CMS maintains the model will lower Medicare spending and patient costs.
The Biotechnology Innovation Organization (BIO), of which MichBio is a state affiliate, along fellow state bioscience associations, Biocom and California Life Sciences, announced the filing of a federal lawsuit recently challenging Medicare’s Global Benchmark for Efficient Drug Pricing (GLOBE) Model, arguing that its reliance on foreign drug prices threatens investment in new medicines while failing to adequately address patients’ affordability challenges.
Filed November 6 in the U.S. District Court for the Northern District of California, the lawsuit asks the court to declare GLOBE unlawful, set aside the rule and prohibit its enforcement. The organizations contend that CMS exceeded the authority Congress granted it to test Medicare payment and service delivery models.
What GLOBE would do
GLOBE is a mandatory model affecting certain medicines administered in clinical settings and covered under Original Medicare Part B, including treatments for cancer and autoimmune conditions. It uses international prices to calculate additional manufacturer rebates when U.S. prices exceed the model’s benchmark.
CMS‘ announcement schedules the model to begin January 1, 2027, with reduced beneficiary coinsurance beginning April 1. It covers selected geographic areas representing approximately one-quarter of Original Medicare beneficiaries. CMS says the model will reduce Medicare spending and patients’ out-of-pocket costs while preserving quality of care. The final design excludes several product categories, including orphan-only drugs and certain cell and gene therapies.
BIO and its partners argue that this approach effectively imports foreign government price controls into the U.S. market. Their complaint challenges CMS’s use of demonstration and waiver authority to create additional rebate obligations and raises constitutional and appropriations-law claims. These are allegations the court must resolve; filing the lawsuit does not itself suspend implementation.
Why emerging biotechnology companies should be concerned
For a company developing its first medicine, expected future revenue helps determine whether investors will finance years of research and clinical trials. BIO warns that reducing those anticipated returns could make capital harder to secure, leading companies to narrow development programs, abandon research or delay expansion.
International licensing creates another concern. In its comments on the proposed model, BIO explained that smaller companies often license foreign commercialization rights to partners and may lack control over, or access to, the resulting overseas prices. Linking U.S. rebate obligations to those prices could expose an American developer to financial consequences driven by decisions it cannot independently change.
For Michigan’s emerging biotechs, the potential implications extend to financing, partnership terms and asset valuations well before a product reaches Medicare patients.
BIO’s challenge also questions whether savings to Medicare necessarily translate into meaningful relief for individual patients. Its lawsuit announcement cites a January analysis estimating that only 0.3% of Part B beneficiaries would experience lower out-of-pocket costs under the proposed GLOBE rule.
BIO also argues that foreign price benchmarks leave other access barriers unresolved, including high cost sharing, prior authorization, step therapy and restrictive coverage policies.
What BIO proposes instead
Alongside its effort to block GLOBE, BIO advocates reforms intended to lower patient costs while preserving incentives to develop new treatments:
-
Reform pharmacy benefit managers and improve discount pass-through, targeting practices that separate manufacturer discounts from what patients pay.
-
Strengthen patient benefits under 340B, so discounted medicines more directly support affordable access for the patients the program serves.
-
Reduce insurance-related access barriers, including burdensome prior authorization and step therapy.
-
Use pharmaceutical trade agreements to encourage other wealthy countries to contribute more toward innovation.
These proposals target different problems: patients’ immediate expenses, delays in obtaining prescribed medicines and the international imbalance in financing drug development.
For Michigan’s bioscience community, the stakes encompass both today’s access to medicines and tomorrow’s pipeline. BIO’s position is that affordability reforms should deliver tangible patient benefits while sustaining the investment that allows promising discoveries to become treatments. Stay tuned on how BIO’s lawsuit plays out.

